United Therapeutics Corp. (Nasdaq: UTHR) reported Q1 non-GAAP EPS of $1.29, $0.65 better than the analyst estimate of $0.64. Revenue for the quarter came in at $165.6 million versus the consensus estimate of $178.02 million.

United Therapeutics reported non-GAAP EPS of $1.13 in Q210.

Earnings